Home
/
Amneal Pharmaceuticals, Inc.
/
Financials
/
Quarterly
Amneal Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Amneal Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$0
May 15, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$784.51M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$724.51M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$695.42M
May 7, 2025
Q3
2025
Sep 30, 2024
$702.47M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$701.78M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$659.19M
May 7, 2025
Q3
2024
Sep 30, 2023
$620.04M
Nov 12, 2024
Q2
2024
Jun 30, 2023
$599.05M
Aug 9, 2024
Q1
2024
Mar 31, 2023
$557.54M
May 8, 2024
Q3
2023
Sep 30, 2022
$545.56M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$559.36M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$497.63M
May 9, 2023
Q3
2022
Sep 30, 2021
$528.59M
Nov 7, 2022
Q2
2022
Jun 30, 2021
$535.08M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$493.11M
May 6, 2022
Q3
2021
Sep 30, 2020
$519.29M
Nov 8, 2021
Q2
2021
Jun 30, 2020
$464.66M
Aug 9, 2021
Q1
2021
Mar 31, 2020
$498.53M
May 7, 2021
Q3
2020
Sep 30, 2019
$378.28M
Nov 6, 2020
Q2
2020
Jun 30, 2019
$404.64M
Aug 6, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$2.37M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$22.42M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$12.20M
May 7, 2025
Q3
2025
Sep 30, 2024
($156.0K)
Nov 6, 2025
Q2
2025
Jun 30, 2024
$5.99M
Aug 7, 2025
Q1
2025
Mar 31, 2024
($91.64M)
May 7, 2025
Q3
2024
Sep 30, 2023
$9.68M
Nov 12, 2024
Q2
2024
Jun 30, 2023
$11.92M
Aug 9, 2024
Q1
2024
Mar 31, 2023
($6.94M)
May 8, 2024
Q3
2023
Sep 30, 2022
($7.61M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($242.13M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($8.82M)
May 9, 2023
Q3
2022
Sep 30, 2021
($7.78M)
Nov 7, 2022
Q2
2022
Jun 30, 2021
$29.99M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$12.75M
May 6, 2022
Q3
2021
Sep 30, 2020
($21.64M)
Nov 8, 2021
Q2
2021
Jun 30, 2020
($24.16M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
$120.43M
May 7, 2021
Q3
2020
Sep 30, 2019
($265.01M)
Nov 6, 2020
Q2
2020
Jun 30, 2019
($16.90M)
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$70.34M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$111.37M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$100.35M
May 7, 2025
Q3
2025
Sep 30, 2024
$88.81M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$95.47M
Aug 7, 2025
Q1
2025
Mar 31, 2024
($10.75M)
May 7, 2025
Q3
2024
Sep 30, 2023
$75.65M
Nov 12, 2024
Q2
2024
Jun 30, 2023
$80.08M
Aug 9, 2024
Q1
2024
Mar 31, 2023
$34.45M
May 8, 2024
Q3
2023
Sep 30, 2022
$44.35M
Nov 9, 2023
Q2
2023
Jun 30, 2022
($198.62M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
$23.31M
May 9, 2023
Q3
2022
Sep 30, 2021
$28.52M
Nov 7, 2022
Q2
2022
Jun 30, 2021
$67.12M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$45.91M
May 6, 2022
Q3
2021
Sep 30, 2020
$2.44M
Nov 8, 2021
Q2
2021
Jun 30, 2020
$10.75M
Aug 9, 2021
Q1
2021
Mar 31, 2020
$57.79M
May 7, 2021
Q3
2020
Sep 30, 2019
($112.27M)
Nov 6, 2020
Q2
2020
Jun 30, 2019
($18.91M)
Aug 6, 2020